Lifeline for anemia patients: drug access extended for those who responded
NCT ID NCT05221619
First seen Jan 05, 2026 · Last updated May 05, 2026 · Updated 20 times
Summary
This program offers continued treatment with nipocalimab to people with warm autoimmune hemolytic anemia (wAIHA) who saw improvement in a previous study. Participants must have completed the earlier 28-week study and still be benefiting from the drug. The goal is to keep their condition under control, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.